SingleCognitive & Sleep

Dihexa 10mg

Synthetic angiotensin IV analog researched for neuroplasticity and HGF/c-Met-mediated synaptogenesis.

Mechanism

Dihexa binds with high affinity to hepatocyte growth factor (HGF), potentiating c-Met receptor phosphorylation and stimulating downstream cascades that drive spinogenesis and synaptogenesis.

Dosing

Research references document 5–10 mg, typically administered sublingually or orally.

Reconstitution

Add 2.0 mL bacteriostatic water to achieve a final working concentration of 5 mg/mL.

Storage

Store lyophilized peptide at −20 °C; once reconstituted, refrigerate at 2–8 °C and protect from light.

Mix & measure Dihexa 10mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Dihexa 10mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration5.00mg/mL

Draw volume1.00mL

On the syringe100.0units

Total doses in vial: 2.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Initiation (Days 1–7)	5 mg once daily	100 units (1.00 mL)
Escalation (Days 8–14)	7.5 mg once daily	150 units (1.50 mL)
Evaluation (Days 15–21)	10 mg once daily	200 units (2.00 mL)

Reconstitution Steps

1
Remove the Dihexa 10mg lyophilized vial and bacteriostatic water from cold storage and allow both to equilibrate to room temperature for 15 to 20 minutes.
2
Disinfect the rubber stoppers of both vials using fresh, sterile alcohol swabs and allow them to air-dry completely.
3
Draw exactly 2.0 mL of bacteriostatic water into a sterile mixing syringe.
4
Insert the needle into the Dihexa vial and slowly dispense the diluent down the inner glass wall to minimize turbulent agitation.
5
Gently swirl and roll the vial between your palms until the powder is fully dissolved into a clear, particle-free solution without shaking.
6
Affix a label indicating the reconstitution date and 5 mg/mL concentration, and transfer the vial to 2–8 °C refrigeration for laboratory storage.

Supplies Needed

Peptide Vial

Provides 10 mg of lyophilized Dihexa research peptide, requiring one vial for every 1 to 2 experimental cycles at the documented 5 to 10 mg parameters.

Insulin Syringes (U-100)

Facilitates accurate aliquot measurement from the 5 mg/mL reconstituted stock, requiring one sterile syringe per scheduled research draw.

Bacteriostatic Water

Supplies the preserved solvent for reconstitution, consuming 2.0 mL per 10 mg vial.

Alcohol Swabs

Used to sanitize vial septa prior to diluent introduction and stock withdrawals, requiring two to three swabs per protocol procedure.

Why researchers study it

Cognitive enhancement

Neuroplasticity

Synaptogenesis

Neurodegeneration research

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, also identified as PNB-0408) is a synthetic oligopeptide derivative of angiotensin IV engineered to address the rapid metabolic degradation typical of native peptide ligands. Designed for enhanced blood-brain barrier permeability and chemical stability, Dihexa serves as a primary reference molecule in preclinical investigations targeting neurotrophic activity, dendritic arborization, and synaptic plasticity. Preclinical studies indicate that Dihexa interacts with hepatocyte growth factor (HGF) to augment c-Met receptor phosphorylation and drive downstream signaling pathways, such as PI3K/Akt, in the central nervous system. In vitro and in vivo models demonstrate that this signaling facilitation can induce robust dendritic spinogenesis and synaptogenesis at picomolar concentrations. While extensively evaluated in preclinical models of cognitive impairment, neurodegeneration, and chemically induced amnesia, Dihexa remains an investigational research compound that is strictly intended for laboratory experimentation and is not approved for clinical diagnostic or therapeutic use.

References

1.McCoy et al., J Pharmacol Exp Ther, 2013 — Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents
2.Benoist et al., J Pharmacol Exp Ther, 2014 — The procognitive and synaptogenic effects of angiotensin IV-derived peptides are mediated by the HGF/c-Met system
3.Sun et al., Brain Sci, 2021 — AngIV-analog Dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway
4.Wright and Harding, Prog Neurobiol, 2015 — The development of small molecule angiotensin IV analogs to treat cognitive deficits